Video scenes shots:
Watch the video:
Other videos by this author:
 |
Dr. Paul Ladenson on Diagnosis of Thyroid Nodules Posted by: OncLiveTV
Video duration: 158 seconds Paul W. Ladenson, MD, John Eager Howard Professor of Endocrinology and Metabolism, Professor of Medicine, Pathology, Oncology, and Radiology & Radiological Sciences, Director, Division of Endocrinology and Metabolism, Johns Hopkins Medicine, discusses differential diagnosis for cytologically indeterminate thyroid nodules. |
 |
AACE 21st Annual Scientific and Clinical Congress Slideshow Posted by: OncLiveTV
Video duration: 51 seconds Photos taken from the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress held at the Pennsylvania Convention Center, from May 23-27, 2012. |
 |
Dr. Maurie Markman on PCP Awareness of Long-Term Chemotherapy Side Effects Posted by: OncLiveTV
Video duration: 89 seconds Maurie Markman, MD, senior vice president for Clinical Affairs, National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, explains that many experts recognize that the long-term care of cancer survivors is beginning to transition towards primary care physicians (PCPs). |
 |
ONS President Mary Gullatte Discusses Cancer Genetic Counseling Posted by: OncLiveTV
Video duration: 70 seconds Mary Gullatte, PhD, RN, APRN, BC, AOCN®, FAAN, associate chief nursing officer, Emory University Hospital Midtown, president, Oncology Nursing Society, discusses some of the concerns surrounding the growing field of cancer genetic counseling. |
![Krista Rubin on Understanding Ipilimumab\](http://img.youtube.com/vi/OB-V_e3y64c&feature=youtube_gdata/2.jpg "Krista Rubin on Understanding Ipilimumab\") |
Krista Rubin on Understanding Ipilimumab's Toxicities Posted by: OncLiveTV
Video duration: 49 seconds Krista Rubin, MS, RN, FNP-BC, Center for Melanoma, Massachusetts General Hospital Cancer Center, explains that it is increasing important that nurses understand the cause immune-related toxicities in patients receiving ipilimumab, an immunotherapy approved for patients with metastatic melanoma. |
 |
Dr. Paul Sieber on Managing Bone Health After the Introduction of ADT Posted by: OncLiveTV
Video duration: 61 seconds Paul R. Sieber, MD, Urological Association of Lancaster, explains that the initial burst of activity following the introduction of androgen-deprivation therapy (ADT) is severe and may result in as much as a 10% loss in bone density. To add perspective, he notes that this amount of bone loss is 3 to 5 times what is lost during menopause in women. |
 |
Dr. Oliver Sartor Discusses Prostate-Specific Antigen (PSA) Screening Posted by: OncLiveTV
Video duration: 70 seconds Oliver Sartor, MD, medical director, Tulane Cancer Center, explains that there is no question that PSA screening detects many cancers that do not need to be treated. To him, the larger question is whether there is enough knowledge to determine which patients should be treated and which should not. Read more at http://www.onclive.c om/onclive-tv/Dr-Oli ver-Sartor-Discusses -PSA-Screening |
 |
Dr. Nancy Davidson on Screening for Ovarian Cancer Posted by: OncLiveTV
Video duration: 75 seconds Nancy E. Davidson, MD, director, University of Pittsburgh Cancer Institute and UPMC Cancer Centers, discusses two methods of screening for ovarian cancer, which have both been proven to be ineffective. |
 |
Dr. Andre Goy on Neoadjuvant Leuprolide and Abiraterone in High Risk Localized Prostate Cancer Posted by: OncLiveTV
Video duration: 95 seconds Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses a phase II trial that combined leuprolide acetate with abiraterone acetate before prostatectomy in patients with localized high-risk prostate cancer. Read more at http://www.onclive.c om/onclive-tv/Dr-Goy -on-Neoadjuvant-Horm onal-Therapy-Plus-Zy tiga |
 |
Dr. Michael Rotkowitz on the Dabrafenib Plus Trametinib Combination for Melanoma Posted by: OncLiveTV
Video duration: 48 seconds Michael Rotkowitz, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses bypassing resistance in patients with melanoma that are receiving vemurafenib. Read more at http://www.onclive.c om/conference-covera ge/asco-2012/Dr-Rotk owitz-on-the-Dabrafe nib-Trametinib-Combi nation |
 |
Dr. Shayma Kazmi on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting Posted by: OncLiveTV
Video duration: 63 seconds Shayma Kazmi, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses olanzapine for breakthrough chemotherapy-induced nausea and vomiting. Read more at http://www.onclive.c om/conference-covera ge/asco-2012/Dr-Kazm i-Discusses-Olanzapi ne-for-Breakthrough- CINV |
 |
Dr. Paul Chapman on BRAF and MEK Inhibitor Combination for Advanced Melanoma Posted by: OncLiveTV
Video duration: 93 seconds Paul B. Chapman, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses combination therapy with dabrafenib and trametinib, two investigational agents for patients with advanced melanoma that have a V600 BRAF mutation. View more at http://www.onclive.c om/conference-covera ge/asco-2012/Dr-Chap man-on-BRAF-MEK-Comb ination-for-Melanoma |
 |
Dr. Neil Spector Discusses Breast Cancer Heterogeneity Posted by: OncLiveTV
Video duration: 136 seconds Neil L. Spector, MD, co-director, Experimental Therapeutics, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, explains the need for an ample interpretation of breast cancer heterogeneity. Read more at http://www.onclive.c om/onclive-tv/Dr-Spe ctor-Explains-Breast -Cancer-Heterogeneit y |
 |
Dr. Stephen Ansell on Treating Patients With Waldenström Macroglobulinemia Posted by: OncLiveTV
Video duration: 61 seconds Stephen Ansell, MD, PhD, professor of medicine at the Mayo Clinic in Minnesota, discusses using rituximab (Rituxan) to treat subgroups of patients with Waldenström Macroglobulinemia (WM), a rare type of slow-growing non-Hodgkin lymphoma. Read more at http://www.onclive.c om/onclive-tv/Dr-Ans ell-on-Treating-Wald enstrm-Macroglobulin emia |
 |
Nurses Discuss the Value of the ONS Annual Congress Posted by: OncLiveTV
Video duration: 210 seconds Five nurses discuss the value of the Oncology Nursing Society (ONS) Annual Congress, which is the largest meeting held specifically for oncology nurses. The meeting offers many ancillary events, as well as satellite symposia and cutting-edge sessions. Read more at http://www.onclive.c om/conference-covera ge/ons-2012/Nurses-D iscuss-the-Value-of- the-ONS-Annual-Congr ess |
 |
Dr. Matthew Ellis on Heterogeneity Impacting Biomarker Efficacy Posted by: OncLiveTV
Video duration: 72 seconds Matthew J. Ellis, MD, PhD, professor of medicine, director, Breast Cancer Program, Siteman Cancer Center, discusses the impact that tumor level heterogeneity has on the efficacy of biomarkers for patients with breast cancer. Read more at http://www.onclive.c om/onclive-tv/Dr-Ell is-on-Heterogeneity- Impacting-Biomarker- Efficacy |
 |
Dr. Robert Dreicer on Utilizing New Prostate Cancer Therapies Posted by: OncLiveTV
Video duration: 61 seconds Robert Dreicer, MD, MS, chairman of the Department of Solid Tumor Oncology at the Taussig Cancer Institute at the Cleveland Clinic, discusses many of the issues that are delaying the utilization of new therapies to treat patients with prostate cancer. Read more at http://www.onclive.c om/onclive-tv/Dr-Dre icer-on-Utilizing-Ne w-Prostate-Cancer-Th erapies |
 |
ONS 37th Annual Congress Slideshow Posted by: OncLiveTV
Video duration: 107 seconds The Oncology Nursing Society 37th Annual Congress, at the New Orleans Ernest N. Morial Convention Center, offers four full days of programming, dozens of exhibitors, satellite symposia, and has thousands of members in attendance. The conference facilitates interactions between oncology nurses from all parts of the US, while ensuring the educational needs of all attendees are met. |
 |
Carol Bush, BS, RN, on the Midwest Cancer Alliance Telehealth Network Posted by: OncLiveTV
Video duration: 77 seconds Carol J. Bush, BS, RN, Patient Navigator, Midwest Cancer Alliance, The University of Kansas Cancer Center, discusses the telehealth network used by the Midwest Cancer Alliance (MCA) to provide access to the ONS Chemotherapy and Biotherapy training for oncology nurses in rural areas. Read more at http://www.onclive.c om/conference-covera ge/ons-2012/Carol-Bu sh-on-the-MCA-Telehe alth-Network |
